Foundayo Eli Lilly Nederland B.V. · Opinion · ATC A10BJ
Therapeutic indication (EMA)
Treatment of obesity and type 2 diabetes mellitus in adults
Active substance
Orforglipron hemicalcium
- EMA 1
- UK MHRA 6
EMA European Union — centrally authorised medicines
UK MHRA United Kingdom — marketing authorisations
| Product | Authorisation | Holder | Legal status |
|---|---|---|---|
| FOUNDAYO 0.8 MG FILM-COATED TABLETS | PL 14895/0369 | ELI LILLY NEDERLAND B.V. | POM |
| FOUNDAYO 14.5 MG FILM-COATED TABLETS | PL 14895/0373 | ELI LILLY NEDERLAND B.V. | POM |
| FOUNDAYO 17.2 MG FILM-COATED TABLETS | PL 14895/0374 | ELI LILLY NEDERLAND B.V. | POM |
| FOUNDAYO 2.5 MG FILM-COATED TABLETS | PL 14895/0370 | ELI LILLY NEDERLAND B.V. | POM |
| FOUNDAYO 5.5 MG FILM-COATED TABLETS | PL 14895/0371 | ELI LILLY NEDERLAND B.V. | POM |
| FOUNDAYO 9 MG FILM-COATED TABLETS | PL 14895/0372 | ELI LILLY NEDERLAND B.V. | POM |
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), MHRA category lists of UK marketing authorisations (Open Government Licence v3.0), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.
Updated